马萨诸塞州萨默维尔讯 - 专注于基因疗法的生物技术公司bluebird bio, Inc.（NASDAQ: BLUE）今日宣布与投资公司Carlyle（NASDAQ: CG）和SK Capital Partners达成收购协议。根据 InvestingPro 数据显示，该公司一直背负着大量债务，现金消耗迅速，当前比率仅为0.51。由生物技术行业高管David ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

当地时间2月21日，蓝鸟生物宣布，将被全球投资公司凯雷和由SK Capital管理的基金收购。Mirati Therapeutics 和益普生（Ipsen）的前首席执行官David Meek预计将在交易完成后成为蓝鸟的首席执行官。

Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ending its ...

Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global ...

Carlyle and SK Capital Partners have agreed to pay $3 in cash for each share of Bluebird, the biotech announced Friday. That price is a 57% discount to the company’s closing stock price Thursday.

Bluebird Bio (BLUE) announced that it has entered into a definitive agreement to be acquired by funds managed by Carlyle (CG) and SK Capital ...

That’s what Carlyle and SK Capital are paying for the 15-year-old Massachusetts biotech in a deal that was announced on Friday. There is a catch. If the private equity firms can boost sales of ...

Bluebird bio to be acquired by Carlyle Group & SK Capital, offering up to $9.84/share based on product performance. Former Mirati CEO David Meek set to lead bluebird post-acquisition, with deal ...

(NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital ...